Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models
- Author(s)
- Nesic, K; Rybinski, K; Ratnayake, G; Ho, GY; Lim, R; Radke, M; Neagle, C; Swisher, EM; Wakefield, MJ; Barker, HE; Furuuchi, K; Scott, CL; Vandenberg, CJ;
- Details
- Publication Year 2025-03,Volume 15,Issue #3,Page e70274
- Journal Title
- Clinical and Translational Medicine
- Publisher
- WIley
- Research Division(s)
- ACRF Cancer Biology and Stem Cells; Bioinformatics and Computational Biology
- PubMed ID
- 40074693
- Publisher's Version
- https://doi.org/10.1002/ctm2.70274
- Open Access at Publisher's Site
https://doi.org/10.1002/ctm2.70274- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-04-10 09:58:39
Last Modified: 2025-05-29 02:41:24